We are live on ! Find out more
COGT icon

Cogent Biosciences
COGT

180 hedge funds and large institutions have $973M invested in Cogent Biosciences in 2025 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 79 increasing their positions, 36 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

214% more call options, than puts

Call options by funds: $20.5M | Put options by funds: $6.52M

119% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 36

22% more capital invested

Capital invested by funds: $800M → $973M (+$174M)

13% more funds holding in top 10

Funds holding in top 10: 8 → 9 (+1)

1.79% more ownership

Funds ownership: 117.25% → 119.04% (+1.8%)

3% less funds holding

Funds holding: 186 → 180 (-6)

14% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 35

Holders
180
Holders Change
-6
Holders Change %
-3.23%
% of All Funds
2.37%
Holding in Top 10
9
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+12.5%
% of All Funds
0.12%
New
30
Increased
79
Reduced
36
Closed
35
Calls
$20.5M
Puts
$6.52M
Net Calls
+$13.9M
Net Calls Change
+$15M

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$15.8M
2
EA
Emerald Advisers
Pennsylvania
+$8.01M
3
PBA
Paradigm Biocapital Advisors
New York
+$7.7M
4
IC
Ikarian Capital
Texas
+$5.74M
5
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
+$4.96M

Top Sellers

Rank Fund Capital Flow
1
CC
Commodore Capital
New York
-$36.5M
2
RG
Redmile Group
California
-$9.8M
3
Franklin Resources
Franklin Resources
California
-$7.95M
4
SG Americas Securities
SG Americas Securities
New York
-$5.68M
5
VA
VR Adviser
New York
-$5.15M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$8.62M +$1.17M +211,475 +21%
VC
27
Vivo Capital
California
$8.06M – – –
IC
28
Ikarian Capital
Texas
$7.44M +$5.74M +1,035,528 New
WP
29
Woodline Partners
California
$7.18M -$3.81M -686,929 -41%
Millennium Management
30
Millennium Management
New York
$6.96M +$2.53M +455,475 +89%
SCM
31
Superstring Capital Management
New York
$6.91M +$1.04M +188,230 +24%
Northern Trust
32
Northern Trust
Illinois
$6.71M +$303K +54,658 +6%
EMFAT
33
Emerald Mutual Fund Advisers Trust
Pennsylvania
$6.43M +$4.96M +895,412 New
Charles Schwab
34
Charles Schwab
California
$6.37M +$336K +60,692 +7%
AG
35
Algert Global
California
$6.2M +$1.86M +335,804 +64%
SL
36
Siren LLC
Connecticut
$6.13M +$4.74M +854,379 New
RSCM
37
Rock Springs Capital Management
Maryland
$5.75M +$4.44M +800,199 New
Citadel Advisors
38
Citadel Advisors
Florida
$4.46M +$729K +131,547 +27%
Dimensional Fund Advisors
39
Dimensional Fund Advisors
Texas
$4.09M -$43.4K -7,827 -1%
EAM
40
Exome Asset Management
New York
$3.83M -$488K -88,031 -14%
KCM
41
Kennedy Capital Management
Missouri
$3.73M +$216K +38,886 +8%
BFM
42
Boothbay Fund Management
New York
$3.6M +$2.78M +502,000 New
TI
43
Trexquant Investment
Connecticut
$3.6M +$1.76M +317,222 +173%
CM
44
Caption Management
Oklahoma
$3.14M +$2.42M +437,228 New
CS
45
Candriam SCA
Luxembourg
$3.07M +$2.37M +427,342 New
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
$2.92M +$1.49M +269,376 +197%
DP
47
Diadema Partners
New Jersey
$2.82M – – –
Barclays
48
Barclays
United Kingdom
$2.3M +$807K +145,647 +83%
HWAM
49
Hennion & Walsh Asset Management
New Jersey
$2.19M +$17.4K +3,134 +1%
SC
50
SummitTX Capital
Texas
$2.15M +$15.6K +2,811 +0.9%
1
2
3 4 5

COGT Hedge Fund Activity: Q2 2025 in Review

180 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q2 2025, worth a combined $973M — up 22% from $800M a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of COGT and 30 opened new positions — a net loss of 5 holders — while 36 trimmed existing stakes and 79 added.

The largest buyer was Janus Henderson Group, adding an estimated $15.8M. The largest seller was Commodore Capital, cutting an estimated $36.5M.

  • 180 institutional investors held Cogent Biosciences (COGT) as of Q2 2025, down from 186 in Q1 2025.
  • Funds reported $973M of Cogent Biosciences stock for Q2 2025, up 22% quarter-over-quarter.
  • 30 funds opened new Cogent Biosciences positions in Q2 2025 and 35 closed out, a net change of -5 holders.
  • The largest Cogent Biosciences buyer in Q2 2025 was Janus Henderson Group, an estimated $15.8M added.
  • The largest Cogent Biosciences seller in Q2 2025 was Commodore Capital, an estimated $36.5M sold.

Based on aggregated 13F filings for Q2 2025.